Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 6.74 1.81% 0.12
AQST closed up 1.81 percent on Wednesday, November 25, 2020, on 34 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical AQST trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.81%
Wide Bands Range Expansion 1.81%
Wide Bands Range Expansion -0.59%
Overbought Stochastic Strength -0.59%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Older End-of-Day Signals for AQST ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 5 hours ago
10 DMA Support about 10 hours ago
Down 1% about 10 hours ago
Up 1% about 10 hours ago
10 DMA Support 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Pharmaceutical Diseases Drugs Psychoactive Drugs Epilepsy Chloroarenes Amyotrophic Lateral Sclerosis Opioids Lactams Gabaa Receptor Positive Allosteric Modulators Parkinson’s Disease Neuroendocrine Tumors Riluzole

Is AQST a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.0
52 Week Low 1.41
Average Volume 932,964
200-Day Moving Average 5.15
50-Day Moving Average 5.86
20-Day Moving Average 6.01
10-Day Moving Average 6.54
Average True Range 0.47
ADX 21.23
+DI 27.75
-DI 17.28
Chandelier Exit (Long, 3 ATRs ) 6.00
Chandelier Exit (Short, 3 ATRs ) 6.05
Upper Bollinger Band 7.36
Lower Bollinger Band 4.65
Percent B (%b) 0.77
BandWidth 45.10
MACD Line 0.32
MACD Signal Line 0.22
MACD Histogram 0.096
Fundamentals Value
Market Cap 226.6 Million
Num Shares 33.6 Million
EPS -2.61
Price-to-Earnings (P/E) Ratio -2.59
Price-to-Sales 3.54
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.15
Resistance 3 (R3) 7.11 6.95 7.08
Resistance 2 (R2) 6.95 6.84 6.96 7.05
Resistance 1 (R1) 6.84 6.78 6.90 6.88 7.03
Pivot Point 6.68 6.68 6.70 6.69 6.68
Support 1 (S1) 6.57 6.57 6.63 6.61 6.45
Support 2 (S2) 6.41 6.51 6.42 6.43
Support 3 (S3) 6.30 6.41 6.40
Support 4 (S4) 6.34